Avalo Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Avalo Therapeutics has a total shareholder equity of $7.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.0M and $13.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$7.42m |
Equity | US$7.30m |
Total liabilities | US$13.69m |
Total assets | US$20.99m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: C6K0's short term assets ($8.4M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: C6K0's short term assets ($8.4M) do not cover its long term liabilities ($9.1M).
Debt to Equity History and Analysis
Debt Level: C6K0 is debt free.
Reducing Debt: C6K0 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: C6K0 has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: C6K0 is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.